Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking A Deep Breath: Novartis & Schering Split Respiratory Product Rights, Giving Novartis Indacaterol

Executive Summary

Novartis is building a respiratory franchise based around its promising chronic obstructive pulmonary disease drug QAB149 (indacaterol) and is taking steps to make sure the world knows it
Advertisement

Related Content

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2010
Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
Spiriva Finds COPD Exacerbation Studies Can Be An Exasperating Experience
Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial
Schering/Novartis To Develop Once-Daily Inhalation Combination For Asthma, COPD

Topics

Advertisement
UsernamePublicRestriction

Register

PS051106

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel